Personalis (NASDAQ:PSNL - Get Free Report) is projected to announce its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $15.48 million for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.
Personalis Stock Down 13.1 %
NASDAQ PSNL traded down $0.71 during mid-day trading on Friday, hitting $4.72. The stock had a trading volume of 1,082,930 shares, compared to its average volume of 1,008,196. Personalis has a 52-week low of $1.13 and a 52-week high of $7.20. The company has a market cap of $333.47 million, a price-to-earnings ratio of -2.81 and a beta of 1.73. The company has a 50 day simple moving average of $5.41 and a 200 day simple moving average of $5.00.
Analysts Set New Price Targets
Several equities analysts recently weighed in on PSNL shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $7.25 price objective on shares of Personalis in a research note on Wednesday, January 8th. Lake Street Capital raised their price objective on Personalis from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, HC Wainwright dropped their price target on Personalis from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Monday, January 27th.
Check Out Our Latest Stock Analysis on Personalis
Personalis Company Profile
(
Get Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Further Reading
Before you consider Personalis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.
While Personalis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
